Tag: vasopressin
Copeptin as a Marker of Outcome After Cardiac Arrest
Copeptin is an independent marker of severity of the post cardiac arrest syndrome, partially related to circulatory failure. 690 patients were included in the analyses, of whom 203 (30.3%) developed cardiovascular deterioration... read more
Renal Outcomes of Vasopressin and Its Analogs in Distributive Shock
In patients with distributive shock, vasopressin and its analogs use is associated with a reduced need for renal replacement therapy and lower acute kidney injury (AKI) incidence. These results are supported by high risk... read more
Terlipressin for Septic Shock Patients
Catecholamines are commonly used in septic shock but face limitations of their hypo-responsiveness and adverse events due to high dose. Terlipressin is a synthetic vasopressin analog with greater selectivity for the V1-receptor.... read more
Heterogeneity of Treatment Effect by Baseline Risk of Mortality in Critically ill Patients
Randomised controlled trials (RCTs) enrolling patients with sepsis or acute respiratory distress syndrome (ARDS) generate heterogeneous trial populations. Non-random variation in the treatment effect of an intervention due... read more
Effect of High-dose Ascorbic Acid on Vasopressor’s Requirement in Septic Shock
In this study, administration of high-dose ascorbic acid significantly decreased the requirement for vasopressor's dose and duration in surgical critically ill patients with septic shock. Several mechanisms including anti-oxidant,... read more
Unintended Consequences: Fluid Resuscitation Worsens Shock in an Ovine Model of Endotoxemia
Fluid resuscitation resulted in a paradoxical increase in vasopressor requirement. Additionally, it did not result in improvements in any of the measured microcirculatory- or organ-specific markers measured. The increase... read more
A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest
In adults with out-of-hospital cardiac arrest, the use of epinephrine resulted in a significantly higher rate of 30-day survival than the use of placebo, but there was no significant between-group difference in the rate of... read more
The Myth of Vasopressors and Ischemia
Despite the widespread clinical use, and their well-documented life-saving properties, vasopressors are often maligned, accused of causing ischemia to fingers, toes, mesentery, kidneys, and so forth. Not only is the evidence... read more
Genomics and Pharmacogenomics of Sepsis: So Close and Yet So Far
Sapru et al. show in this issue of Critical Care that variants of thrombomodulin and the endothelial protein C receptor, but not protein C, are associated with mortality and organ dysfunction (ventilation-free and organ failure-free... read more
Acute Kidney Injury in Sepsis
Acute kidney injury (AKI) and sepsis carry consensus definitions. The simultaneous presence of both identifies septic AKI. Septic AKI is the most common AKI syndrome in ICU and accounts for approximately half of all such... read more
The Septic Shock 3.0 Definition and Trials
Ranjit Deshpande, MD, speaks with James A. Russell, MD, about the article, "The Septic Shock 3.0 Definition and Trials: A Vasopressin and Septic Shock Trial Experience," published in the June 2017 issue of Critical Care Medicine.... read more
Vasopressin vs. norepinephrine for vasoplegic shock after cardiac surgery
Patients in the VANISH trial treated with vasopressin had a lower incidence of renal failure requiring hemodialysis. However, this was a secondary endpoint which seemed to contradict the primary endpoint (defined as a milder... read more
